Adjuvant chemotherapy for breast cancer in older women: Emerging evidence to aid in decision making

Current Treatment Options in Oncology

Volumn 12, Issue 3, 2011, Pages 286-301

  Kimmick, Gretchen ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BCG VACCINE; CAPECITABINE; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; FLUOXYMESTERONE; GRANULOCYTE COLONY STIMULATING FACTOR; HORMONE RECEPTOR; METHOTREXATE; PACLITAXEL; PREDNISONE; TAMOXIFEN; TAXANE DERIVATIVE; THIOTEPA; TRASTUZUMAB; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADJUVANT THERAPY; ADVERSE OUTCOME; ANEMIA; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER RELAPSE; CANCER RISK; CANCER SURVIVAL; COMORBIDITY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG MEGADOSE; DRUG SAFETY; EVIDENCE BASED MEDICINE; FEBRILE NEUTROPENIA; FEMALE; FRAIL ELDERLY; FUNCTIONAL STATUS; GERIATRIC CARE; HUMAN; LIFE EXPECTANCY; LOW DRUG DOSE; MEDICAL DECISION MAKING; MULTIPLE CYCLE TREATMENT; NAUSEA; PATIENT ASSESSMENT; PERIPHERAL NEUROPATHY; PHYSICAL PERFORMANCE; PROGRESSION FREE SURVIVAL; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SEPSIS; SINGLE DRUG DOSE; SURVIVAL RATE; TREATMENT INDICATION;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DECISION MAKING; FEMALE; GERIATRIC ASSESSMENT; HUMANS; LIFE EXPECTANCY; RECURRENCE; RISK ASSESSMENT;

EID: 80054982747     PISSN: 15272729     EISSN: 15346277     Source Type: Journal    
DOI: 10.1007/s11864-011-0159-z     Document Type: Article

References (79)

1. Yancik R. Cancer burden in the aged-an epidemiologic and demographic overview. Cancer. 1997;80 (7):1273.
2. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics. CA Cancer J Clin. 2010;60(5):277-300.
3. Yancik R, Ries LG, Yates JW. Breast cancer in aging women. A population-based study of contrasts in stage, surgery, and survival. Cancer. 1989;63:976.
4. Bouchardy C, Rapiti E, Fioretta G, et al. Undertreatment strongly decreases prognosis of breast cancer in elderly women. J Clin Oncol. 2003;21 (19):3580.
5. Du XL, Key CR, Osborne C, Mahnken JD, Goodwin JS. Discrepancy between consensus recommendations and actual community use of adjuvant chemotherapy in women with breast cancer. Ann Intern Med. 2003;138(2):90-7. (Pubitemid 36222495)
6. Wyld L, Garg DK, Kumar ID, Brown H, Reed MW. Stage and treatment variation with age in postmenopausal women with breast cancer: compliance with guidelines. Br J Cancer. 2004;90(8):1486-91. (Pubitemid 38648226)
7. Abe O, Abe R, Enomoto K, et al. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687.
8. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2- positive breast cancer. N Engl J Med. 2005;353 (16):1673-84. (Pubitemid 41464706)
9. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2- positive breast cancer. N Engl J Med. 2005;353 (16):1659-72. (Pubitemid 41464705)
10. Kimmick G, Hughes K, Muss HB. Breast cancer in older women. In: Harris JR, Lippman ME, Morrow M, Osborne CK, editors. Diseases of the breast, vol fourth. Philadelphia: Lippincott Williams & Wilkins; 2009. p. 1059-72.
11. Berry DA, Cirrincione C, Henderson IC, et al. Estrogen- receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. Jama. 2006;295(14):1658-67.
12. Clarke M, Coates AS, Darby SC, et al. Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials, Early Breast Cancer Trialists' Collaborative Group. Lancet. 2008;371(9606):29-40.
13. MussHB, Woolf S, Berry D, et al. Adjuvant chemotherapy in older and younger women with lymph nodepositive breast cancer. JAMA. 2005;293(9):1073-81. (Pubitemid 40300281)
14. Giordano SH, Duan Z, Kuo YF, Hortobagyi GN, Goodwin JS. Use and outcomes of adjuvant chemotherapy in older women with breast cancer. J Clin Oncol. 2006;24(18):2750-6. (Pubitemid 46630572)
15. Elkin EB, Hurria A, Mitra N, Schrag D, Panageas KS. Adjuvant chemotherapy and survival in older women with hormone receptor-negative breast cancer: assessing outcome in a population-based, observational cohort. J Clin Oncol. 2006;24(18):2757-64. (Pubitemid 46630573)
16. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351(27):2817-26. (Pubitemid 40051905)
17. Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol. 2006;24(23):3726-34. (Pubitemid 46622311)
18. Tian S, Roepman P, Van't Veer LJ, Bernards R, de Snoo F, Glas AM. Biological functions of the genes in the mammaprint breast cancer profile reflect the hallmarks of cancer. Biomarkers Insights. 2010;5:129-38.
19. Wittner BS, Sgroi DC, Ryan PD, et al. Analysis of the MammaPrint breast cancer assay in a predominantly postmenopausal cohort. Clin Cancer Res. 2008;14 (10):2988-93.
20. Muss HB, Berry DA, Cirrincione C, et al. Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B Experience. J Clin Oncol. 2007;25(24):3699-704. (Pubitemid 47372610)
21. Crivellari D, Bonetti M, Castiglione-Gertsch M, et al. Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Groups Trial VII. J Clin Oncol. 2000;18:1412.
22. Kimmick GG, Fleming R, Muss HB, Balducci L. Cancer chemotherapy in older adults-a tolerability perspective. Drugs Aging. 1997;10(1):34-49. (Pubitemid 27057936)
23. Wildiers H. Challenges in treating older cancer patients: breast cancer. Ann Oncol. 2008;Suppl 7: vii99-103.
24. Lichtman SM, Wildiers H, Chatelut E, et al. International society of geriatric oncology chemotherapy taskforce: evaluation of chemotherapy in older patients-an analysis of the medical literature. J Clin Oncol. 2007;25(14):1832-43. (Pubitemid 46860272)
25. Launay-Vacher V, Spano JP, Janus N, et al. Renal insufficiency and anticancer drugs in elderly cancer patients: a subgroup analysis of the IRMA study. Crit Rev Oncol Hematol. 2009;70(2):124-33.
26. Baraldi-Junkins CA, Beck AC, Rothstein G. Hematopoiesis and cytokines. Relevance to cancer and aging. Hematol Oncol Clin North Am. 2000;14(1):45-61. viii. (Pubitemid 30078431)
27. Balducci L, Al-Halawani H, Charu V, et al. Elderly cancer patients receiving chemotherapy benefit from first-cycle pegfilgrastim. Oncologist. 2007;12 (12):1416-24.
28. Patt DA, Duan Z, Fang S, Hortobagyi GN, Giordano SH. Acute myeloid leukemia after adjuvant breast cancer therapy in older women: understanding risk. J Clin Oncol. 2007;25(25):3871-6. (Pubitemid 47477263)
29. Renella R, Verkooijen HM, Fioretta G, et al. Increased risk of acute myeloid leukaemia after treatment for breast cancer. Breast. 2006;15(5):614-9. (Pubitemid 44509769)
30. Pinder MC, Duan Z, Goodwin JS, Hortobagyi GN, Giordano SH. Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J Clin Oncol. 2007;25 (25):3808-15. (Pubitemid 47477254)
31. Hurria A, Lachs MS, Cohen HJ, Muss HB, Kornblith AB. Geriatric assessment for oncologists: rationale and future directions. Crit Rev Oncol Hematol. 2006;59(3):211-7. (Pubitemid 44279423)
32. Extermann M, Balducci L, Lyman GH. What threshold for adjuvant therapy in older breast cancer patients? J Clin Oncol. 2000;18(8):1709-17. (Pubitemid 30220549)
33. Ferrucci L, Guralnik JM, Cavazzini C, et al. The frailty syndrome: a critical issue in geriatric oncology. Crit Rev Oncol Hematol. 2003;46(2):127-37. (Pubitemid 36444632)
34. Extermann M, Hurria A. Comprehensive geriatric assessment for older patients with cancer. J Clin Oncol. 2007;25(14):1824-31. (Pubitemid 46860271)
35. Extermann M, Aapro M, Bernabei R, et al. Use of comprehensive geriatric assessment in older cancer patients: recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG). Crit Rev Oncol Hematol. 2005;55 (3):241-52. (Pubitemid 41219694)
36. Inouye SK, Studenski S, Tinetti ME, Kuchel GA. Geriatric syndromes: clinical, research, and policy implications of a core geriatric concept. J Am Geriatr Soc. 2007;55(5):780-91. (Pubitemid 46668974)
37. Maas HA, Janssen-Heijnen ML, Olde Rikkert MG, Machteld Wymenga AN. Comprehensive geriatric assessment and its clinical impact in oncology. Eur J Cancer. 2007;43(15):2161-9.
38. Hurria A, Gupta S, Zauderer M, et al. Developing a cancer-specific geriatric assessment: a feasibility study. Cancer. 2005;104(9):1998-2005. (Pubitemid 41513186)
39. Hurria A, Cirrincione CT, Muss HB, et al. Implementing a geriatric assessment in Cooperative Group Clinical Cancer Trials: CALGB 360401. J Clin Oncol. 2011
40. Satariano WA, Ragland DR. The effect of comorbidity on 3-year survival of women with primary breast cancer. Ann Intern Med. 1994;120:104.
41. Satariano WA. Aging, comorbidity, and breast cancer survival: an epidemiologic view. Adv Exp Med Biol. 1993;330:1.
42. Bergman L, Dekker G, van Leeuwen FE, Huisman SJ, Van Dam FS, van Dongen JA. The effect of age on treatment choice and survival in elderly breast cancer patients. Cancer. 1991;67:2227.
43. Hurria A, Hurria A, Zuckerman E, et al. A prospective, longitudinal study of the functional status and quality of life of older patients with breast cancer receiving adjuvant chemotherapy. J Am Geriatr Soc. 2006;54(7):1119-24. (Pubitemid 43992551)
44. Schairer C, Mink PJ, Carroll L, Devesa SS. Probabilities of death from breast cancer and other causes among female breast cancer patients. J Natl Cancer Inst. 2004;96(17):1311.
45. Ferrucci L, Guralnik JM, Studenski S, Fried LP, Cutler Jr GB, Walston JD. Designing randomized, controlled trials aimed at preventing or delaying functional decline and disability in frail, older persons: a consensus report. J Am Geriatr Soc. 2004;52(4):625-34. (Pubitemid 38480644)
46. Rockwood K, Howlett SE, MacKnight C, et al. Prevalence, attributes, and outcomes of fitness and frailty in community-dwelling older adults: report from the Canadian study of health and aging. J Gerontol A Biol Sci Med Sci. 2004;59(12):1310-7. (Pubitemid 40209418)
47. Mor V, Wilcox V, Rakowski W, Hiris J. Functional transitions among the elderly: patterns, predictors, and related hospital use. Am J Public Health. 1994;84(8):1274-80. (Pubitemid 24250697)
48. Dittus K, Muss HB. Management of the frail elderly with breast cancer.Oncology (Williston Park). 2007;21 (14):1727-34. discussion 1737, 1740.
49. Repetto L, Fratino L, Audisio RA, et al. Comprehensive geriatric assessment adds information to Eastern Cooperative Oncology Group performance status in elderly cancer patients: an Italian group for geriatric oncology study. J Clin Oncol. 2002;20(2):494.
50. Monfardini S, Ferrucci L, Fratino L, del Lungo I, Serraino D, Zagonel V. Validation of a multidimen- Practical Adjuvant Breast Cancer Treatment in Older Women Kimmick 299 sional evaluation scale for use in elderly cancer patients. Cancer. 1996;77(2):395-401.
51. Fried LP, Ferrucci L, Darer J, Williamson JD, Anderson G. Untangling the concepts of disability, frailty, and comorbidity: implications for improved targeting and care. J Gerontol A Biol Sci Med Sci. 2004;59(3):255-63. (Pubitemid 38375339)
52. Song X, Mitnitski A, Rockwood K. Prevalence and 10- year outcomes of frailty in older adults in relation to deficit accumulation. J Am Geriatr Soc. 2010;58 (4):681-7.
53. Saliba D, Elliott M, Rubenstein LZ, et al. The Vulnerable Elders Survey: a tool for identifying vulnerable older people in the community. J Am Geriatr Soc. 2001;49(12):1691-9. (Pubitemid 34007998)
54. Fried LP, Xue QL, Cappola AR, et al. Nonlinear multisystem physiological dysregulation associated with frailty in older women: implications for etiology and treatment. J Gerontol A Biol Sci Med Sci. 2009;64(10):1049-57. Frailty is multifactorial and addressing only one component will probably not fully ameliorate the problem
55. Cohen HJ, Harris T, Pieper CF. Coagulation and activation of inflammatory pathways in the development of functional decline and mortality in the elderly. Am J Med. 2003;114(3):180-7. (Pubitemid 36294002)
56. Walston J, Hadley EC, Ferrucci L, et al. Research agenda for frailty in older adults: toward a better understanding of physiology and etiology: summary from the American Geriatrics Society/National Institute on Aging Research Conference on Frailty in Older Adults. J Am Geriatr Soc. 2006;54(6):991-1001. (Pubitemid 43847040)
57. Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001;56(3):M146-56. (Pubitemid 32187141)
58. Singh MA. Exercise to prevent and treat functional disability. Clin Geriatr Med. 2002;18(3):431-62. vi-vii. (Pubitemid 34966688)
59. Leveille SG, Guralnik JM, Ferrucci L, Langlois JA. Aging successfully until death in old age: opportunities for increasing active life expectancy. Am J Epidemiol. 1999;149(7):654-64. (Pubitemid 29162715)
60. Landi F, Cesari M, Onder G, Lattanzio F, Gravina EM, Bernabei R. Physical activity and mortality in frail, community-living elderly patients. J Gerontol A Biol Sci Med Sci. 2004;59(8):833-7. (Pubitemid 39167427)
61. Extermann M, Meyer J, McGinnis M, et al. A comprehensive geriatric intervention detects multiple problems in older breast cancer patients. Crit Rev Oncol Hematol. 2004;49(1):69.
62. Hurria A, Togawa K, Mohile SG, et al. Predicting chemotherapy toxicity in older adults with cancer: A prospective 500 patient multicenter study. J Clin Oncol. 2010;28(15s):abstr 9001.
63. Extermann M, Boler I, Reich R, et al. The Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score: design and validation. J Clin Oncol. 2010;28(15s):abstr 9000.
64. Hutchins LF, Unger JM, Crowley JJ, Coltman CA, Albain KS. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med. 1999;341:2061.
65. Murthy VH, Krumholz HM, Gross CP. Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA. 2004;291(22):2720-6. (Pubitemid 38725421)
66. Kimmick G, Kornblith A, Mandelblatt J, et al. A randomized controlled trial of an educational program to improve accrual of older persons to cancer treatment protocols: CALGB 360001. J Clin Oncol. 2004;22(14):739S.
67. Slamon D, Eiermann W, Robert N, et al. Phase III trial comparing AC-T with AC-TH and with TCH in the adjuvant treatment of HER2 positive early breast cancer patients: second interim efficacy analysis. 29th Annual SABCS. 2006(Abstract 52)
68. Jones SE, Collea RP, Oratz R, et al. Cardiac safety results of a phase II trial of adjuvant docetaxel/cyclophosphamide plus trastuzumab (Her TC) in HER2+ early stage breast cancer patients. Cancer Res. 2009;69(24 Supplement):5082.
69. Doyle JJ, Neugut AI, Jacobson JS, Grann VR, Hershman DL. Chemotherapy and cardiotoxicity in older breast cancer patients: a population-based study. J Clin Oncol. 2005;23(34):8597-605. (Pubitemid 46211501)
70. Jones SE, Savin MA, Holmes FA, et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol. 2006;24 (34):5381-7. (Pubitemid 46623169)
71. Jones S, Holmes FA, O'Shaughnessy J, et al. Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US oncology research trial 9735. J Clin Oncol. 2009;27 (8):1177-83
72. Fisher B, Brown AM, Dimitrov NV, et al. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared 300 Geriatric Oncology with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol. 1990;8:1483.
73. De Maio E, Gravina A, Pacilio C, et al. Compliance and toxicity of adjuvant CMF in elderly breast cancer patients: a single-center experience. BMC Cancer. 2005;5:30.
74. Lyman GH, Shayne M. Granulocyte colony-stimulating factors: finding the right indication. Curr Opin Oncol. 2007;19(4):299-307. (Pubitemid 46883517)
75. Muss HB, Berry DA, Cirrincione CT, et al. Adjuvant chemotherapy in older women with early-stage breast cancer. N Engl J Med. 2009;360(20):2055-65.
76. Citron ML, Berry DA, Cirrincione C, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of intergroup trial C9741/cancer and leukemia group B trial 9741. J Clin Oncol. 2003;21 (8):1431.
77. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406 (6797):747-52.
78. Ma CX, Sanchez CG, Ellis MJ. Predicting endocrine therapy responsiveness in breast cancer. Oncology (Williston Park). 2009;23(2):133-42.
79. Fargeot P, Bonneterre J, Roche H, et al. Disease-free survival advantage of weekly epirubicin plus tamoxifen versus tamoxifen alone as adjuvant treatment of operable, node-positive, elderly breast cancer patients: 6-year follow-up results of the French adjuvant study group 08 trial. J Clin Oncol. 2004;22 (23):4622-30. (Pubitemid 41185076)